Table 2. Summary of treatment parameters of the selected studies.
| Reference, Year | Sample Size | SBRT Dose, Fractionation, Timing | Image Guidance | ADT | LN Treatment | Rectal Management |
|---|---|---|---|---|---|---|
| Quon, 2018 | 152 | 40, q7d 40, q2d | CBCT | < 6 months | NR | NR |
| Boyer, 2017 | 60 | 37.5, 5, q2d | CBCT | None | None | Milk of Mg, fleet enema |
| Hannan, 2016 | 91 | 33.5, 5, q2d | NR | <9 months | None | NR |
| Rucinska, 2016 | 68 | 33.5, 5, q3d | MVCT | Yes, unspecified | None | NR |
| Shikama, 2016 | 20 | 35, 5, q2d | CyberKnife | ≤ 8 months | NR | NR |
| D’Agostino, 2016 | 90 | 35, 5, q2d | CBCT | ≤ 6 months | NR | NR |
| Bauman, 2015 | 15 | 40, 5, q1w | CBCT | ≤ 12 months | 25 Gy in 5 fx | NR |
| Bernetich, 2014 | 142 | 35/36.25/37, 5, q2d | CyberKnife | None | NR | NR |
| Kim, 2014 | 91 | 45/47.5/50, 5, q7d | CyberKnife | NR | NR | Milk of Mg + rectal balloon |
| King, 2013 | 1100 | 35–40, 5, qd | Cyberknife | ≤ 3 months | None | NR |
| Loblaw, 2013 | 84 | 35, 5, q1w | NR | 4 months | NR | NR |
| Alongi, 2013 | 40 | 35, 5, q2d | CBCT | Per NCCN guidelines | NR | SpaceOAR hydrogel |
| McBride, 2011 | 45 | 36.3–37.5, 5, qd | CyberKnife | None | NR | Yes, unspecified |
| Madsen, 2007 | 40 | 33.5, 5, qd | NR | NR | NR | NR |
Abbreviations: NR, not reported; SBRT, stereotactic body radiation therapy; ADT, androgen deprivation therapy; LN, lymph node; CBCT, cone-beam computed tomography; Mg; magnesia; MVCT, megavoltage computed tomography; Gy, Gray; fx, fractions; NCCN, National Comprehensive Cancer Network.